AML
Conference Coverage
Treatment for WDTC tied to increased risk of AML
MADRID—New research suggests patients with well-differentiated thyroid cancer (WDTC) are more likely to develop acute myeloid leukemia (AML) if...
News
CCSs have higher burden of chronic conditions
Adult survivors of childhood cancer have a greater cumulative burden of chronic health conditions than the general public, according to research...
Latest News
New AML approvals changing the treatment landscape
A recent flurry of new drug approvals for acute myeloid leukemia are raising questions about how to incorporate these costly new therapies into...
News
Studies of donor CAR T cells placed on hold
The US Food and Drug Administration (FDA) has placed a clinical hold on both phase 1 studies of UCART123, a universal (allogeneic) chimeric...
News
Withdrawn AML drug back on market in US
The US Food and Drug Administration (FDA) has approved use of gemtuzumab ozogamicin (GO, Mylotarg), a treatment that was initially approved by the...
News
FDA reapproves gemtuzumab ozogamicin for CD33-positive AML treatment
Initial approval for gemtuzumab ozogamicin was granted in May 2000 as a stand-alone treatment for CD33-positive AML in older patients, but was...
From the Journals
Enasidenib data in IDH2-mutated AML are basis for combination therapy trials
Enasidenib monotherapy was well tolerated and active in a phase 1/2 trial involving patients with relapsed or refractory IDH2-mutated AML.
News
Vitamin C regulates HSCs, curbs AML development
Researchers have described a molecular mechanism that could help explain the link between low vitamin C (ascorbate) levels and acute myeloid...
News
Antibody could treat AML, MM, and NHL
An investigational antibody has demonstrated activity against acute myeloid leukemia (AML), multiple myeloma (MM), and non-Hodgkin lymphoma (NHL...
News
FDA grants drug orphan designation for AML
The US Food and Drug Administration (FDA) has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML). SY-...
News
FDA grants drug orphan designation for AML, CMML
The US Food and Drug Administration (FDA) has granted orphan drug designation to H3B-8800 as a treatment for patients with acute myelogenous...